ArticleTechnology in cancer research & treatment
TNFRSF10B, a Therapeutic Target for Oral Squamous Cell Carcinoma Through Integrated Bioinformatics and Preliminary Experiments.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundTumor necrosis factor receptor superfamily member (10B TNFRSF10B), as a key apoptosis regulator of Oral Squamous Cell Carcinoma (OSCC), exerts a critical effect on its development.MethodsDifferentially expressed genes in OSCC (GSE25099) were screened first. Weighted gene co-expression network analysis identified gene modules, followed by Lasso regression and Cox modeling to pinpoint pivotal genes. Expression was validated in the Cancer Genome Atlas databases and in clinical samples. The Search Tool for the Retrieval of Interacting Genes/Proteins database was used to generate a protein-protein interaction (PPI) network, and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses explored biological functions. Then, for in vitro assays, core gene-targeted siRNAs were introduced into SCC-4 and SCC-9 cell lines to mediate gene knockdown. Cell proliferation was quantified by the CCK-8 method, and apoptotic activity was assessed via flow cytometry, TUNEL staining, and Western blotting for apoptosis-associated proteins.ResultsAmong the 10 core genes that were further screened, TNFRSF10B was most notably linked to unfavorable OSCC prognosis and showed strong diagnostic power. Additionally, its overexpression was associated with clinical stage, nodal metastasis, and chemoresistance. PPI and enrichment analyses revealed its role in extrinsic and necroptotic apoptosis. Moreover, the knockdown of TNFRSF10B suppressed viability and induced apoptosis by upregulating Bax, downregulating Bcl-2, and activating Caspase-3/PARP.ConclusionsTNFRSF10B drives OSCC progression by impairing apoptosis. Its overexpression correlates with poor prognosis and represents a potential diagnostic and therapeutic target. Furthermore, targeting TNFRSF10B may restore apoptosis, thus making precision therapy achievable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.